The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Midodrine Hydrochloride Morningside 2.5 mg tablets



Aspire Pharma (Malta) LimitedPA23142/008/001

Main Information

Trade NameMidodrine Hydrochloride Morningside 2.5 mg tablets
Active SubstancesMidodrine hydrochloride
Dosage FormTablet
Licence HolderAspire Pharma (Malta) Limited
Licence NumberPA23142/008/001

Group Information

ATC CodeC01CA17 midodrine

Status

License statusAuthorised
Licence Issued16/09/2022
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportPDF Version

Generics Information

Interchangeable ListMidodrine 2.5mg Tablets
Interchangeable List CodeIC0120-018-002
Interchangeable List DocumentPDF of Interchangeable List
« Back